Lineage Cell Therapeutics
Carlsbad · Founded 1990
About Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs. The company is focused on developing new therapeutics for age-related degenerative disease. BioTime and its subsidiaries are developing OpRegen® (a cell-based therapy for age-related macular degeneration), therapies for cancer, and arthritis, respectively. Our subsidiary ReCyte Therapeutics is using proprietary technology to reverse the developmental aging of human cells to manufacture young vascular progenitors for the treatment of age-related vascular disease. Relatively near-term product development by BioTime and its subsidiaries include Renevia, a patented hyaluronan-based hydrogel device for cell delivery; PanC-Dx, a blood-based pan-cancer screening diagnostic; and re-starting the embryonic stem cell-based clinical trial for spinal cord injury that was originally begun by Geron, using the stem cell assets acquired from them in 2013. BioTime also markets an FDA-approved blood plasma expander called Hextend®, which is currently marketed in collaboration with Hospira.
Company Facts
- Founded: 1990
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $164.8M
- Funding stage: IPO
- Last round: Grant (Aug 2025)
- Ticker: nysemkt:LCTX
- Website: lineagecell.com
- Phone: +1 442 287 8963
Industries & Categories
Biopharma, Biotechnology, Environmental Consulting, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/lineage-cell-therapeutics-35630 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.